| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Low affinity immunoglobulin gamma Fc region receptor II-a, IgG Fc receptor II-a, CDw32, Fc-gamma RII-a, Fc-gamma-RIIa, FcRII-a, CD32, FCGR2A, CD32, FCG2, FCGR2A1, IGFR2 |
| Entrez GeneID | 2212 |
| WB Predicted band size | 35.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This FCGR2A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 256-285 amino acids from the C-terminal region of human FCGR2A. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于FCGR2A抗体的3篇代表性文献及其摘要内容：
1. **文献名称**：*FCGR2A polymorphisms and clinical outcomes in rituximab-treated non-Hodgkin lymphoma patients*
**作者**：Cartron G, et al.
**摘要**：该研究探讨了FCGR2A基因多态性(H131R)对利妥昔单抗(抗CD20单抗)疗效的影响，发现携带纯合子FCGR2A-131H等位基因的患者对治疗反应更佳，提示该受体在抗体依赖性细胞介导的细胞毒作用(ADCC)中的关键作用。
2. **文献名称**：*FCGR2A and FCGR3A polymorphisms correlate with response to anti-CD20 therapy in autoimmune diseases*
**作者**：Clatworthy MR, et al.
**摘要**：研究分析了FCGR2A和FCGR3A基因多态性与B细胞清除疗法(如利妥昔单抗)在系统性红斑狼疮等自身免疫病中的疗效关联，发现特定FCGR2A变异可影响抗体介导的免疫细胞活化及治疗效果。
3. **文献名称**：*Role of FCGR2A in malaria susceptibility and antibody-dependent respiratory burst activity*
**作者**：Ouma C, et al.
**摘要**：该文献揭示FCGR2A的H131R多态性与疟疾感染易感性相关，其中R等位基因可能降低抗体介导的吞噬作用，影响宿主对疟原虫的免疫清除能力。
4. **文献名称**：*Fc receptor biology and therapeutic targeting in diseases*
**作者**：Bruhns P, et al.
**摘要**：综述总结了FCGR2A在抗体效应功能(如ADCC、吞噬)中的作用机制，并讨论了针对该受体的抗体疗法在癌症和感染性疾病中的潜在应用。
这些文献涵盖了FCGR2A在肿瘤免疫治疗、自身免疫病及感染性疾病中的功能及临床意义。
FCGR2A (Fc gamma receptor IIA) is a cell surface receptor belonging to the immunoglobulin superfamily, primarily expressed on immune cells such as macrophages, neutrophils, and platelets. It binds to the Fc region of IgG antibodies, playing a critical role in mediating immune responses, including phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and clearance of immune complexes. FCGR2A functions through activation signaling via its immunoreceptor tyrosine-based activation motif (ITAM), though its activity is balanced by inhibitory Fc gamma receptors (e.g., FCGR2B) to prevent hyperactivation.
Genetic polymorphisms in FCGR2A, particularly the H131R variant (histidine to arginine at position 131), influence receptor affinity for IgG subclasses. The H131 allele binds IgG2 more efficiently, impacting susceptibility to infections and autoimmune diseases. For instance, the R131 allele is linked to reduced clearance of immune complexes, correlating with higher risks of systemic lupus erythematosus (SLE) and rheumatoid arthritis.
FCGR2A-targeting antibodies are valuable tools in research and therapeutics. They are used to study receptor-ligand interactions, immune cell activation, and disease mechanisms. Clinically, anti-FCGR2A antibodies or modulators are explored in autoimmune disorders and cancer immunotherapy to enhance or inhibit Fc-mediated effector functions. Additionally, FCGR2A’s role in platelet aggregation links it to cardiovascular research, particularly in heparin-induced thrombocytopenia (HIT) pathogenesis. Understanding FCGR2A biology aids in developing tailored therapies for immune dysregulation and inflammatory conditions.
×
